Cirmtuzumab Explained

Type:	mab
Source:	zu
Target:	ROR1
Legal Status:	Investigational
Cas Number:	1643432-38-5
Unii:	FEH7RQ7B3J
Synonyms:	UC-961

Cirmtuzumab (also UC-961) is an anti-ROR1 humanised monoclonal antibody.^{[1] [2]}

It is an experimental drug in early-stage clinical trials for various cancers including chronic lymphocytic leukemia (CLL).^[3]

Notes and References

1. Cirmtuzumab (UC-961), a First-in-Class Anti-ROR1 Monoclonal Antibody: Planned Interim Analysis of Initial Phase 1 Cohorts . 2015 . Choi MY, Widhopf GF, Castro J, Li H, Kidwell RL, Zhang SC, Juarez T, Gorak S, Rassenti LZ, Messer K, Prussak C . 6 . Blood . 126 . 23 . 1736 . 10.1182/blood.V126.23.1736.1736 .
2. News: Researchers to test novel drug combination against toughest breast cancers. Medical Express. 2018-08-27.
3. News: 1st Mantle Cell Lymphoma Patient Dosed in Phase 1/2 Trial Testing Cirmtuzumab-Imbruvica Combo. Lymphoma News Today. 2018-05-18.